Miscelenous Immunoglobulines

Indications & Dose:

Prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients

DOSAGE INSTRUCTION AND DURATION OF ADMINISTRATION

As a rule doses corresponds to 1ml, should be administered. Administration should be initiated on the day of transplantation or the day prior to this (bone marrow transplantation). an initiation of prophylaxis up to 10 days before transplantation can also be envisaged, particularly in CMV seropositive patients. A total of at least 6 doses at 2 to 3 weeks intervals should be given. Route of administration: The solution is intended for intravenous administration. Cytotect should be infused intravenously at a rate of max 20 drops (1ml) per minute. cytotect should be inspected visually for particulate matter and discoloration prior to administration. Do not use solutions which are cloudy or which have a deposit. Cytotect should be warmed to room or body temperature before administration.

UNDESIRABLE EFFECTS: Adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally. Rarely human immunoglobulins may cause a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the patient has shown no hypersensitivity previous administration. Cases of reversible aseptic meningitis, isolated cases of reversible haemolytic anaemia/haemolysis and rare cases of transient cutaneous reactions, have been observed with human immunoglobulin. Increase in serum creatinine level and/or acute renal failure have been observed. Thrombotic events have been reported in the elderly. in patients with signs of cerebral or cardiac ischemia, and in overweight and severely hypovolemic patients.

Contraindications:

cytotech is contraindication in patients who are intolerant to homologous immunoglobulins, especially in very rare cases of lgA deficiency, if the patient has antibodies against lgA.

Side Effects:

Cautions:

Precautions:

Interaction:

Warnings:

Adverse Effects:

Lactations:

Pregnancy and Lactation: The Safety of this medicinal product ofr use in human pregnancy has not been established in controlled clinical trails and therefore should only be given with caution to pregnant women or breast-feeding mothers. Long lasting clinical experience with immunoglobulins does indicate that no harmful effects on the course of pregnancy, on the foetus and the neonate are to be expected. Immunoglobulins are excreted into the milk and may contribute to the transfer of protective antibodies to the neonate.

Special Precautions:

Counselling:

Side Effects Or Adverse Reactions:

Patient And Carer Advice: